Bipolar depression: Issues in diagnosis and treatment

Harvard Review of Psychiatry

Volumn 13, Issue 5, 2005, Pages 257-271

  Thase, Michael E ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Bipolar I disorder; Bipolar II disorder; Depression; Unipolar depression

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; DULOXETINE; FLUOXETINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MILNACIPRAN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NORFLUOXETINE; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

AUTONOMIC NEUROPATHY; BEHAVIOR THERAPY; BIPOLAR DEPRESSION; BODY WEIGHT DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; DIABETES MELLITUS; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG INDICATION; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FAMILY HISTORY; FAMILY THERAPY; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOMANIA; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; METABOLIC DISORDER; MONOTHERAPY; MOOD DISORDER; ONSET AGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; HUMANS; PROGNOSIS;

EID: 27544439064     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220500326425     Document Type: Review

References (154)

1. Murray CJL, Lopez AD, eds. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press, 1996.
2. Angst J. Bipolar disorder - a seriously underestimated health burden. Eur Arch Psychiatry Clin Neurosci 2004;254:59-60.
3. Weissman MM, Bland RC, Camino GH, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276:293-9.
4. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64:53-9.
5. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the EGA database taking into account subthreshold cases. J Affect Disord 2003;73:123-31.
6. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003;64:161-74.
7. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7.
8. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-9.
9. Kupfer DJ, Frank E, Grochocinski VJ, et al. Stabilization in the treatment of mania, depression and mixed states. Acta Neuropsychiatr 2000;12:110-4.
10. Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 2003;17:491-511.
11. Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry 2003;64(suppl 5):44-52.
12. Joffe RT, MacQueen GM, Marriott M, Robb J, Begin H, Young LT. Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. Acta Psychiatr Scand 2002;105:427-30.
13. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000;61:804-8.
14. Sachs GS, Koslow CL, Ghaemi SN. The treatment of bipolar depression. Bipolar Disord 2000;2:256-60.
15. Perris C. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand 1966;42(suppl 194):1-188.
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: APA, 1980.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC: APA, 2000.
18. Goodwin FK, Jamison KR. Manic-depressive illness. London: Oxford University Press, 1990.
19. Akiskal HS, Walker P, Puzantian VR, King D, Rosenthal TL, Dranon M. Bipolar outcome in the course of depressive illness. Phenomenologic, familial, and pharmacologic predictors. J Affect Disord 1983;5:115-28.
20. Winokur G, Coryell W, Keller M, Endicott J, Leon A. A family study of manic-depressive (bipolar I) disease. Is it a distinct illness separable from primary unipolar depression? Arch Gen Psychiatry 1995;52:367-73.
21. Benazzi F. Depression with DSM-IV atypical features: a marker for bipolar II disorder. Eur Arch Psychiatry Clin Neurosci 2000;250:53-5.
22. Mitchell PB, Wilhelm K, Parker G, Austin M-P, Rutgers P, Malhi GS. The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. J Clin Psychiatry 2001;62:212-6.
23. Perugi G, Akiskal HS, Lattanzi L, et al. The high prevalence of "soft" bipolar (II) features in atypical depression. Compr Psychiatry 1998;39:63-71.
24. Sharma V. Loss of response to antidepressants and subsequent refractoriness: diagnostic issues in a retrospective case series. J Affect Disord 2001;64:99-106.
25. Sharma V, Khan M, Smith A. A closer look at treatment resistant depression: is it due to a bipolar diathesis? J Affect Disord 2005;84:251-7.
26. Akiskal HS. Searching for behavioral indicators of bipolar II in patients presenting with major depressive episodes: the "red sign," the "rule of three" and other biographic signs of temperamental extravagance, activation and hypomania. J Affect Disord 2005;84:279-90.
27. Wong IC, Besag FM, Santosh PJ, Murray ML. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf 2004;27:991-1000.
28. Chun BJ, Dunner DL. A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. Bipolar Disord 2004;6:32-42.
29. Peet M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164:549-50.
30. Akiskal HS, Hantouche EG, Allilaire JF, et al. Validating antidepressant-associated hypomania (bipolar III): a systematic comparison with spontaneous hypomania (bipolar II). J Affect Disord 2003;73:65-74.
31. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000;157:1873-5.
32. Manning JS, Haykal RF, Akiskal HS. The role of bipolarity in depression in the family practice setting. Psychiatr Clin North Am 1999;22:689-703.
33. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-47.
34. Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol Psychiatry 2000;48:558-72.
35. Ghaemi SN, Rosenquist KJ, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2004;161:163-5.
36. Bottlender R, Rudolf D, Jager M, Strauss A, Möller HJ. Are bipolar I depressive patients less responsive to treatment with antidepressants than unipolar depressive patients? Results from a case control study. Eur Psychiatry 2002;17:200-5.
37. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003;5:421-33.
38. Möller HJ, Bottlender R, Grunze H, Strauss A, Wittmann J. Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression? J Affect Disord 2001;67:141-6.
39. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(suppl 4):1-50.
40. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The expert consensus guideline series. Medication treatment of bipolar disorder 2000. Postgrad Med Spec Rep 2000;Apr:1-104.
41. Keck PE, Perlis RH, Otto MW, Carpenter D, Ross R, Docherty JP. The expert consensus guideline series. Treatment of bipolar disorder 2004. Postgrad Med Spec Rep 2004;December:1-119.
42. Suppes T, Dennehy EB, Swann AC, et al. Report of the Texas consensus conference panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002;63:288-99.
43. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry 2004;38:280-305.
44. Calabrese JR, Kasper S, Johnson G, et al. International consensus group on bipolar I depression treatment guidelines. J Clin Psychiatry 2004;65:571-9.
45. Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003;17:149-73.
46. Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Bipolar Disorders. World Federation of of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry 2002;3:115-24.
47. Keck PE Jr, McElroy SL. New approaches in managing bipolar depression. J Clin Psychiatry 2003;64(suppl 1):13-8.
48. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-12.
49. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-3.
50. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002;159:1005-10.
51. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003;290:1467-73.
52. Davis L, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005;85:259-66.
53. Sachs G, Altshuler L, Ketter T, et al. Divalproex sodium versus placebo for the treatment of bipolar depression. Poster presented at the American College of Neuropsychopharmacology, Waikoloa, HI, December, 2001.
54. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 2002;26:530-6.
55. Gyulai L, Bowden CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003;28:1374-82.
56. Post RM, Frye MAQ, Denicoff KD, Leverich GS, Kimbrell TA, Dunn RT. Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology 1998;19:206-19.
57. Hirschfeld RM, Kasper S. A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 2004;7:507-22.
58. Ketter TA, Kalali AH, Weisler RH; SPD417 Study Group. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004;65:668-73.
59. Marangell LB, Martinez JM, Ketter TA, et al., STEP-BD Investigators. Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD. Bipolar Disord 2004;6:139-43.
60. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999;60:79-88.
61. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-14.
62. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000;61:841-50.
63. Calabrese J, Sachs G, Hirschfeld RMA, et al. Efficacy and safety of lamotrigine in acute bipolar depression: findings from three completed studies. Presented at the 45th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June, 2005.
64. Brown E, Williamson D, Deldar A, Keck PE, Adams DH. Olanzapine-fluoxetine combination versus lamotrigine for bipolar depression. Presented at the 45th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June, 2005.
65. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400.
66. Calabrese JR, Bowden CL, Sachs G, et al., for the Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013-24.
67. Hahn CG, Gyulai L, Baldassano CF, Lenox RH. The current understanding of lamotrigine as a mood stabilizer. J Clin Psychiatry 2004;65:791-804.
68. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65:432-41.
69. Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 2002;63:146-51.
70. Bowden CL, Asnis GM, Ginsberg LD, Bentley B, Leadbetter R, White R. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004;27:173-84.
71. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002;63:1012-9
72. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999;156:1164-9.
73. Berk M, Dodd S. Efficacy of atypical antipsychotics in bipolar disorder. Drugs 2005;65:257-69.
74. Kennedy SH, Lam RW. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord 2003;5(suppl 2):36-47.
75. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000;57:841-9
76. (erratum in Arch Gen Psychiatry 2002;59:91).
77. Chengappa KN, Baker RW, Shao L, et al. Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disord 2003;5:1-5.
78. Vieta E, Calabrese JR, Hennen J, et al. Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. J Clin Psychiatry 2004;65:1420-8.
79. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45.
80. Baker RW, Tohen M, Fawcett J, et al. Acute dysphoric mania: treatment response to olanzapine versus placebo. J Clin Psychopharmacol 2003;23:132-7.
81. Baker RW, Brown E, Akiskal HS, et al. Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br J Psychiatry 2004;185:472-8.
82. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88
83. (erratum in Arch Gen Psychiatry 2004;61:176).
84. Shi L, Namjoshi MA, Swindle R, et al. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther 2004;26:125-34.
85. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-60.
86. Hirschfeld RM, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004;161:1057-65.
87. Zajecka J, Murray S, Ramey T, Mandel FS. Efficacy of ziprasidone in dysphoric mania. Presented at the 45th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June, 2005.
88. Keck PE Jr, Marcus R, Tourkodimitris S, et al., Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8.
89. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. J Clin Psychiatry 2003;64:1426-35.
90. Brown RR, Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol 2005;20:105-12.
91. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004;70:1-17.
92. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64:701-23.
93. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000;23:250-62.
94. Bottlender R, Rudolf D, Strauss A, Möller HJ. Mood stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord 2001;63:79-83.
95. Thase ME, Bhargava M, Sachs GS. Treatment of bipolar depression: current status, continued challenges, and the STEP-BD approach. Psychiatr Clin North Am 2003;26:495-518.
96. Cohn JB, Collins G, Ashbrook E, Wenicke JF. A comparison of fluoxetine, imipramine, and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4:313-22.
97. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000;157:124-6.
98. Vieta E, Martinhez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002;63:508-12.
99. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004;65:1715-9.
100. Fagiolini A, Buysse DJ, Frank E, Houck PR, Luther JF, Kupfer DJ. Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression. J Clin Psychopharmacol 2001;21:474-8.
101. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a pooled analysis of original data from seven randomized controlled trials. J Clin Psychiatry (in press).
102. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002;4:207-13.
103. Thase ME, Entsuah RA, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
104. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404.
105. Thase ME, Friedman ES, Howland RH. Venlafaxine and treatment-resistant depression. Depress Anxiety 2000;12(suppl 1):55-62.
106. Post RM, Leverich GS, Altshuler LL, et al. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord 2003;5:310-9.
107. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502-8.
108. Buckley NA, Faunce TA. 'Atypical' antidepressants in overdose: clinical considerations with respect to safety. Drug Saf 2003;26:539-51.
109. Cheeta S, Schifano F, Oyefeso A, Webb L, Ghodse AH. Antidepressant- related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 2004;184:41-7.
110. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36:106-32.
111. Thase ME. Comparing the efficacy of the newer antidepressants. In: Gilaberte I, ed. Neuvas Perspectivas en la Depresion. Madrid: Aula Medica Ediciones, 2004:253-86.
112. Perahia D, Pritchett YL, Lee TC, Tran PF. Comparing duloxetine and venlafaxine in the treatment of major depressive disorder using a global benefit-risk approach. Presented at the 45th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June, 2005.
113. Thase ME, Tran PV, Wiltse C, Pangallo BA, Mallinckrodt C, Detke MJ. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005;25:132-40.
114. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004;55:320-2.
115. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2003;53:1028-42.
116. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12:185-219.
117. Himmelhoch JM, Fuchs CZ, Symons BJ. A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis 1982;170:628-34.
118. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 2001;148:910-6.
119. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression: IV. A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992;149:195-8.
120. Beasley CM, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL. Possible monoamine oxidase inhibitor-serotonin reuptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993;13:312-20.
121. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999;20:226-47.
122. Angst J, Stabl M. Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology 1992;106:S109-13.
123. Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand 2001;104:104-9.
124. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003;64:208-14.
125. Altshuler LL, Frye MA, Gitlin MJ. Acceleration and augmentation strategies for treating bipolar depression. Biol Psychiatry 2003;53:691-700.
126. Bauer M, London ED, Rasgon N, et al. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol Psychiatry 2005;10:456-69.
127. Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord 2004;6:416-20.
128. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564-6.
129. Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 2004;20:131-8.
130. Sohn CH, Lam RW. Treatment of seasonal affective disorder: unipolar versus bipolar differences. Curr Psychiatry Rep 2004;6:478-85.
131. Black DW, Winokur G, Nasrallah A. ECT in unipolar and bipolar disorders: a naturalistic evaluation of 460 patients. Convuls Ther 1986;2:231-7.
132. Thase ME. The role of psychotherapy in the management of bipolar disorder. In: Kasper S, Hirschfeld RMA, eds. Handbook of bipolar disorder. New York: Marcel Dekker (in press).
133. Lam DH, Watkins ER, Hayward P, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry 2003;60:145-52.
134. Frank E, Kupfer DJ, Thase ME, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry (in press).
135. Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003;60:904-12.
136. Baumgartner A. Thyroxine and the treatment of affective disorders: an overview of the results of basic and clinical research. Int J Neuropsychopharmacol 2000;2:149-65.
137. 4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry 1999;156:1909-14.
138. Cole DP, Thase ME, Mallinger AG, et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry 2002;159:116-21.
139. Goldberg JF, Whiteside JE. The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. J Clin Psychiatry 2002;63:791-5.
140. Weiss RD. Treating patients with bipolar disorder and substance dependence: lessons learned. J Subst Abuse Treat 2004;27:307-12.
141. Salloum IH, Thase ME. Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disord 2000;2:269-80.
142. Hadjipavlou G, Mok H, Yatham LN. Pharmacotherapy of bipolar II disorder: a critical review of current evidence. Bipolar Disord 2004;6:14-25.
143. Yatham LN. Diagnosis and management of patients with bipolar II disorder. J Clin Psychiatry 2005;66(suppl 1):13-7.
144. Akiskal HS, Benazzi F. Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II? J Affect Disord 2005;84:209-17.
145. Hantouche EG, Akiskal HS. Bipolar II vs. unipolar depression: psychopathologic differentiation by dimensional measures. J Affect Disord 2005;84:127-32.
146. Kupfer DJ, Carpenter LL, Frank E. Is bipolar II a unique disorder? Compr Psychiatry 1988;29:228-36.
147. Amsterdam JD, Shults J, Brunswick DJ, Hundert M. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression-low manic switch rate. Bipolar Disord 2004;6:75-81.
148. Amsterdam JD, Brunswick DJ. Antidepressant monotherapy for bipolar type II major depression. Bipolar Disord 2003;5:388-95.
149. Amsterdam JD, Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affect Disord 2000;59:225-9.
150. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60.
151. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161:217-22.
152. Sachs GS, Thase ME. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry 2000;48:573-81.
153. Altshuler L, Kiriakos L, Calcagno J, et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 2001;62:612-6.
154. Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003;160:1252-62.